CD4 and neoplasm: On occasion, these protein variants may be processed into small peptides by a tumor cell’s proteasome and bind the major histocompatibility complex (MHC) molecules with sufficient affinity to serve as novel tumor antigens (i.e., tumor neoantigens) that can then be recognized by CD4+ or CD8+ T cells and elicit an antitumor response (6, 7).